Shots:

• The Independent Data Monitoring Committee (IDMC) recommends for the termination of P-III MERU trial due to lack of survival benefits for patients receiving Rova-T vs PBO control arm based on results at a pre-planned interim analysis
• The P-III MERU trial is discontinued with the closure of R&D program for Rova-T and the trial involves assessing of Rova-T as maintenance therapy following 1L platinum-based chemotherapy in patients with advanced SCLC evaluating its safety and efficacy
• Rova-T is an investigational ADC targeting cancer-stem cell-associated delta-like protein 3 (DLL3). Additionally- AbbVie oncology portfolio is evaluated in 300+ trials and in more than 20 different tumor type

Click here to read full press release/ article

Ref: AbbVie| Image: AbbVie